Home » Vetter’s Development Service Doubles Its Revenues, Grows Capabilities
Vetter’s Development Service Doubles Its Revenues, Grows Capabilities
Vetter Pharma International
Vetter, a leading contract development and manufacturing organization (CDMO), reports that its Development Service doubled its revenues over the last five years, due to increased customer demand for support on complex biologics. Vetter Development Service (VDS) supports products from preclinical development through Phase III and develops robust processes that enable a seamless transfer to Vetter Commercial Manufacturing. Offering a continuum of service, the global VDS organization comprises more than 150 scientists, engineers and other personnel. Vetter’s Chicago facility provides early-stage clinical production, featuring equipment optimized for small-batch manufacturing. Ravensburg facilities support a range of development products through Phase III and feature sophisticated new technologies with enhanced analytical capabilities.
Since the full operational launch of VDS Chicago, Vetter´s first U.S. facility, in October 2011, the site has contracted with a number of companies from around the globe, including Belgium, Israel and Korea, in addition to the United States. Supporting preclinical through Phase II products, the site has already released customer batches for clinical trials. Over the past few months, the Chicago site has expanded analytical and microbial testing; added 2,000 square feet of GMP storage; and built out its business office to accommodate more than 20 additional work spaces. Future plans include adding a third cleanroom to the two existing ones, which will expand current operations and provide filling of pre-sterilized syringes.
As part of its continuous investment in its state-of-the-art facilities, over the last year Vetter acquired sophisticated new technologies at its Ravensburg development labs that enable better control of syringe and cartridge siliconization; more-accurate detection of sub-visible particles in drug products; and a greater ability to simulate commercial-level processes in the VDS setting, for even smoother product transfer to commercial production.
"The growth of VDS demonstrates the increasing need for expert support in the development of complex compounds, to address a growing market, said Paul Nelles, Ph.D., vice president of Vetter Development Service. "This rise in demand confirms our decision to expand Vetter Development Service to North America, as was urged by our U.S.-based customers."
Merck Stops Development of Parkinson’s DrugFrom Bloomberg
Merck & Co. will end development of preladenant because a preliminary review of late-stage clinical trials suggests it doesn’t work
French Drugmaker on Trial for Suspected DeathsFrom Yahoo! News
Servier Laboratories, French drugmaker responsible for producing diabetes and weight loss drug Mediator, faces charges for deception in relation to the suspected deaths of hundreds of people.
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
- All news »